May 11, 2006
Janssen Pharma - Seeks European Approval on Long Acting Risperdal/Paliperidone
Pharmaceuticals Business Review announced this week that Janssen Pharmaceuticals has submitted an application for approval of their new long-acting release version of their schizophrenia drug Risperdal / Paliperidone.
Johnson & Johnson, via its subsidiary Janssen has filed an application to European regulators seeking approval to market its prolonged release schizophrenia drug, paliperidone prolonged release tablets. Paliperidone, which releases drug into the bloodstream steadily over a 24-hour period, is an extended release version of Johnson & Johnson's blockbuster schizophrenia treatment Risperdal.
Posted by szadmin at May 11, 2006 01:00 PM
More Information on
Schizophrenia Medications
Comments
Hello,I am from Romania.
I don't have schizophrenia but scizoafectice diorder.
What I want to ask is :if I can take the same medication as schizophrenic patients.
Am I going to have scizophrenia later?(to develop it?)
Posted by: GIF ROMEO at May 22, 2006 11:37 AM
Post a comment
Hello,I am from Romania.
I don't have schizophrenia but scizoafectice diorder.
What I want to ask is :if I can take the same medication as schizophrenic patients.
Am I going to have scizophrenia later?(to develop it?)
Posted by: GIF ROMEO at May 22, 2006 11:37 AM